tradingkey.logo

Metagenomi Inc

MGX
1.760USD
+0.100+6.02%
收盤 12/19, 16:00美東報價延遲15分鐘
66.08M總市值
虧損本益比TTM

Metagenomi Inc

1.760
+0.100+6.02%

關於 Metagenomi Inc 公司

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.

Metagenomi Inc簡介

公司代碼MGX
公司名稱Metagenomi Inc
上市日期Feb 09, 2024
CEOIrish (Jian)
員工數量202
證券類型Ordinary Share
年結日Feb 09
公司地址5959 Horton St
城市EMERYVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94608
電話15108714880
網址https://metagenomi.co/
公司代碼MGX
上市日期Feb 09, 2024
CEOIrish (Jian)

Metagenomi Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.36M
-0.16%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
824.33K
+42.76%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.58%
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Director
Director
--
--
,
,
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
--
--
Dr. Juergen Eckhardt, M.D.
Dr. Juergen Eckhardt, M.D.
Independent Director
Independent Director
--
--
Ms. Pamela M. (Pam) Wapnick
Ms. Pamela M. (Pam) Wapnick
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. Willard H. Dere, M.D.
Dr. Willard H. Dere, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.36M
-0.16%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
824.33K
+42.76%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.58%
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Director
Director
--
--
,
,
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
--
--
Dr. Juergen Eckhardt, M.D.
Dr. Juergen Eckhardt, M.D.
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Bayer HealthCare LLC
10.79%
Thomas (Brian C)
6.29%
Humboldt Capital, LLC
5.05%
The Vanguard Group, Inc.
3.31%
Bernales (Sebastian Ph.D.)
3.12%
其他
71.44%
持股股東
持股股東
佔比
Bayer HealthCare LLC
10.79%
Thomas (Brian C)
6.29%
Humboldt Capital, LLC
5.05%
The Vanguard Group, Inc.
3.31%
Bernales (Sebastian Ph.D.)
3.12%
其他
71.44%
股東類型
持股股東
佔比
Corporation
15.85%
Individual Investor
13.45%
Investment Advisor
7.83%
Hedge Fund
3.18%
Venture Capital
3.00%
Investment Advisor/Hedge Fund
1.70%
Research Firm
1.39%
Sovereign Wealth Fund
0.67%
其他
52.93%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
156
7.24M
19.30%
-9.50M
2025Q2
159
20.26M
54.19%
-7.71M
2025Q1
157
20.44M
54.67%
-7.64M
2024Q4
143
21.51M
57.48%
-2.78M
2024Q3
116
23.74M
63.40%
-1.13M
2024Q2
94
26.05M
69.54%
+4.67M
2024Q1
65
26.68M
71.20%
+16.22M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Bayer HealthCare LLC
4.05M
10.79%
--
--
Sep 30, 2024
Thomas (Brian C)
2.37M
6.31%
-10.79K
-0.45%
Jun 06, 2025
Humboldt Capital, LLC
1.90M
5.05%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.26M
3.35%
-199.55K
-13.69%
Jun 30, 2025
Bernales (Sebastian Ph.D.)
1.17M
3.12%
--
--
Apr 14, 2025
Irish (Jian)
579.04K
1.54%
-6.39K
-1.09%
Jun 06, 2025
Sozo Ventures LLC
581.58K
1.55%
--
--
Jun 30, 2025
Catalio Capital Management, LP
528.99K
1.41%
--
--
Jun 30, 2025
Peapod Lane Capital LLC
508.11K
1.35%
+155.65K
+44.16%
Jun 30, 2025
Millennium Management LLC
383.03K
1.02%
+197.93K
+106.92%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Growth ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Metagenomi Inc的前五大股東是誰?

Metagenomi Inc的前五大股東如下:
Bayer HealthCare LLC
持有股份:4.05M
佔總股份比例:10.79%。
Thomas (Brian C)
持有股份:2.37M
佔總股份比例:6.31%。
Humboldt Capital, LLC
持有股份:1.90M
佔總股份比例:5.05%。
The Vanguard Group, Inc.
持有股份:1.26M
佔總股份比例:3.35%。
Bernales (Sebastian Ph.D.)
持有股份:1.17M
佔總股份比例:3.12%。

Metagenomi Inc的前三大股東類型是什麼?

Metagenomi Inc 的前三大股東類型分別是:
Bayer HealthCare LLC
Thomas (Brian C)
Humboldt Capital, LLC

有多少機構持有Metagenomi Inc(MGX)的股份?

截至2025Q3,共有156家機構持有Metagenomi Inc的股份,合計持有的股份價值約為7.24M,占公司總股份的19.30% 。與2025Q2相比,機構持股有所增加,增幅為-34.89%。

哪個業務部門對Metagenomi Inc的收入貢獻最大?

在--,--業務部門對Metagenomi Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI